■结节病是一种病因不明的慢性炎症性疾病,与高发病率和死亡率相关。其与心血管结局的关联记录不足。
■本研究的目的是评估结节病与非结节病患者的心血管不良结局。
■在线数据库,包括PubMed,Embase和Scopus从成立到2022年3月都受到了质疑。评估的结果包括全因死亡率(ACM)和室性心动过速(VT)的发生率,心力衰竭(HF)和房性心律失常(AA)。
■共有6项研究,有22,539,096名参与者(42,763例结节病,此分析包括22,496,354非结节病)。结节病的合并患病率为13.1%(95%CI1%至70%)。总体平均年龄为47岁。最常见的合并症是高血压(12.7%vs12.5%),和糖尿病(分别为5.5%和4%)。主要终点的汇总分析表明,全因死亡率(RR,2.08;95%CI:1.17~3.08;p=0.01)在结节病患者中显著升高。次要终点的汇总分析表明,VT的发生率(RR,15.3;95%CI:5.39至43.42);p<0.001),HF(RR,4.96;95%CI:2.02至12.14;p<0.001)和AA(RR,2.55;95%CI:1.47至4.44);p=0.01)与结节病相比,结节病分别显着高于非结节病。
■室性心动过速的发生率,CS患者中HF和AA显著增高。临床医生应该意识到这些与结节病相关的不良心血管事件。
UNASSIGNED: Sarcoidosis is a chronic inflammatory disorder of unknown etiology associated with high morbidity and mortality. Its association with cardiovascular outcomes is under-documented.
UNASSIGNED: The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis.
UNASSIGNED: Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA).
UNASSIGNED: A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p < 0.001), HF (RR, 4.96; 95% CI: 2.02 to 12.14; p < 0.001) and AA (RR, 2.55; 95% CI: 1.47 to 4.44); p = 0.01) were significantly higher with sarcoidosis respectively compared to non-sarcoidosis.
UNASSIGNED: Incidence of VT, HF and AA was significantly higher in patients with CS. Clinicians should be aware of these adverse cardiovascular events associated with sarcoidosis.